Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.